Fig. 3From: Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATEPlot of tumour absorbed dose per unit AA (Gy/GBq) vs a the kidney absorbed dose per AA and b patient weight are shown as a function of individual treatment cycle. No correlation observedBack to article page